Twenty-four seven
7074
Land
8918
Tripleize
5026
Remixpoint
3825
Solasia Pharma KK
4597
(FY)Mar 20, 2024 | (FY)Mar 20, 2023 | (FY)Mar 20, 2022 | (FY)Mar 20, 2021 | (FY)Mar 20, 2020 | (FY)Mar 20, 2019 | |
---|---|---|---|---|---|---|
Total revenue | 4.92%4.83B | -3.63%4.61B | -2.01%4.78B | 5.79%4.88B | 7.87%4.61B | 4.28B |
Cost of revenue | 5.10%4.09B | -5.30%3.89B | -1.60%4.11B | 5.33%4.18B | 9.18%3.97B | 3.63B |
Gross profit | 3.97%740.51M | 6.63%712.25M | -4.45%667.98M | 8.68%699.06M | 0.42%643.23M | 640.52M |
Operating expense | 1.16%666.26M | 2.01%658.64M | 5.03%645.66M | 0.18%614.76M | -3.18%613.69M | 633.82M |
Operating profit | 38.48%74.25M | 140.20%53.62M | -73.52%22.32M | 185.38%84.29M | 340.52%29.54M | 6.71M |
Net non-operating interest income (expenses) | 38.25%-486K | 14.27%-787K | 11.39%-918K | -8.60%-1.04M | -97.52%-954K | -483K |
Non-operating interest income | 0.00%6K | 0.00%6K | -71.43%6K | 0.00%21K | -4.55%21K | --22K |
Non-operating interest expense | -37.96%492K | -14.18%793K | -12.58%924K | 8.41%1.06M | 93.07%975K | --505K |
Net investment income | -7.09%393K | -6.62%423K | -6.21%453K | -5.85%483K | -69.15%513K | 1.66M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||
Gain(Loss) on derecognition of available-for-sale financial assets | 365K | |||||
Income from associates and other participating interests | ||||||
Special income (charges) | 0 | -9,840.27%-43.94M | 98.97%-442K | 24.55%-42.97M | -1,023.36%-56.94M | -5.07M |
Less:Other special charges | ---- | ---- | 145.57%442K | -101.70%-970K | 6,399.00%56.94M | ---904K |
Less:Write off | --0 | --43.94M | --0 | --43.94M | ---- | --5.97M |
Other non-operating income (expenses) | -0.11%16.83M | 26.45%16.85M | 60.87%13.32M | -38.63%8.28M | -62.96%13.49M | 36.43M |
Income before tax | 247.75%90.99M | -24.68%26.16M | -29.19%34.74M | 450.71%49.06M | -135.65%-13.99M | 39.24M |
Income tax | 783.70%31.17M | -134.68%-4.56M | -60.66%13.15M | 628.30%33.42M | -138.94%-6.33M | 16.25M |
Net income | 94.69%59.82M | 42.31%30.72M | 38.06%21.59M | 304.09%15.64M | -133.32%-7.66M | 23M |
Net income continuous operations | 94.69%59.82M | 42.31%30.72M | 38.06%21.59M | 304.09%15.64M | -133.32%-7.66M | --23M |
Noncontrolling interests | ||||||
Net income attributable to the company | 94.68%59.82M | 42.31%30.72M | 38.07%21.59M | 304.07%15.64M | -133.32%-7.66M | 23M |
Preferred stock dividends | ||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 94.68%59.82M | 42.31%30.72M | 38.07%21.59M | 304.07%15.64M | -133.32%-7.66M | 23M |
Gross dividend payment | ||||||
Basic earnings per share | 94.69%12.46 | 42.22%6.4 | 38.04%4.5 | 304.23%3.26 | -133.32%-1.5963 | 4.791 |
Diluted earnings per share | 94.69%12.46 | 42.22%6.4 | 38.04%4.5 | 304.23%3.26 | -133.32%-1.5963 | 4.791 |
Dividend per share | 100.00%0.5 | 0.00%0.25 | 0.00%0.25 | 0.00%0.25 | -99.00%0.25 | 25 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |